Table 2.

Screening Method by Country

Site (by region and country)	No. Sites	No. On-site Screening Programs	Screening Method					No. Sites with Electronic Medical Records
			Pap	VIA	VILI	HPV	Colpo/bx
Central Africa (n=6)
Burundi	3	0	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Cameroon	2	2	2(100)	0(0)	0(0)	1(50)	0(0)	0(0)
Rwanda	1	0	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
East Africa (n=18)
Kenya	6	6	5(83)	6(100)	2(33)	3(50)	0(0)	5(83)
Tanzania	5	5	1(20)	5(100)	1(20)	1(20)	0(0)	0(0)
Uganda	7	2	1(50)	2(100)	1(50)	0(0)	0(0)	0(0)
Southern Africa (n=19)
Botswana	2	2	2(100)	1(50)	1(50)	1(50)	1(50)	1(50)
Lesotho	1	1	1(100)	1(100)	0(0)	0(0)	0(0)	1(100)
Malawi	7	7	3(43)	7(100)	2(29)	2(29)	1(14)	1(14)
South Africa	5	4	4(100)	2(50)	1(25)	2(50)	2(50)	3(75)
Zambia	2	2	0(0)	2(100)	0(0)	0(0)	(0)0	2(100)
Zimbabwe	2	2	1(50)	2(100)	0(0)	0(0)	1(50)	2(100)
West Africa (n=8)
Burkina Faso	1	1	1(100)	1(100)	1(100)	1(100)	0(0)	1(100)
Côte d’Ivoire	2	1	1(100)	1(100)	1(100)	0(0)	0(0)	0(0)
Nigeria	2	2	2(100)	1(50)	1(50)	1(50)	0(0)	1(50)
Senegal	2	1	1(100)	0(0)	0(0)	1(100)	0(0)	0(0)
Togo	1	1	1(100)	0(0)	0(0)	0(0)	0(0)	0(0)
	51	39	26(67)	31(79)	11(28)	13(33)	5(13)	17(44)

Data are n(%)

Denominator is the number of on-site screening programs

Pap – Papanicolaou test, VIA -visual inspection with acetic acid, VILI - visual inspection with Lugol’s solution, HPV – human papilloma virus DNA test, colpo/bx – colposcopy +/− biopsy